Annual reports
Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
-
Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
-
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
-
AstraZeneca prices a $2bn bond issue
-
Lynparza significantly reduces the risk of disease worsening or death in patients with BRCA-mutated metastatic breast cancer
-
Directorate Change
Upcoming events
CFA Society
Citi Healthcare Conference (management participation)
Download available
J.P.Morgan Cazenove European Healthcare Conference
Download available
Annual Report
2016
2015
2006-2014
Investor enquiries
Main Contacts
-
Annual Reports
Our Annual Report provides a wide range of information about our global business.
-
Shareholder FAQs
Answers to frequently asked shareholder questions.
-
Our Pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development
